Therapy for filovirus infection

ABSTRACT

The present invention addresses a need for improved treatments for filovirus infections.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application No. 61/830,325 filed Jun. 3, 2013, the contents of which are hereby incorporated by reference.

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under grant number R01-AI090249 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

Throughout this application, various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

Ebola virus (EBOV) pathogenesis and cell entry: The infectious agents EBOV and Marburg virus (MARV) are the two major species of the Filoviridae family of enveloped negative-sense RNA viruses (1-4). Based on nucleotide sequence and outbreak location, isolates in the EBOV species are classified into five species: Zaire (ZEBOV), Tai Forest (TAFV), Sudan (SUDV), Reston (RESTV), and Bundibugyo (BDBV). There are two MARV variants (Marburg and Ravn). Severe human disease and deaths (30-90% case fatality rates in large outbreaks) are associated with ZEBOV, SUDV, BDBV, and MARV (2). Although the ecology of these agents remains incompletely understood, several species of African fruit bats may be reservoirs for EBOV and MARV (5). ZEBOV and SUDV are the most pathogenic among the ebolaviruses, and are the only two that have been associated with recurring outbreaks (6). Among the 13 documented ZEBOV outbreaks and the six SUDV outbreaks, the average human case fatality rates are 70% and 52%, respectively. Together, ZEBOV and SUDV account for 94% of EBOV-related deaths (6). Therefore, therapeutic agents effective against ZEBOV and SUDV would greatly reduce the threat of an EBOV pandemic.

All human outbreaks occur as a result of direct contact with infected wildlife, with subsequent person-to-person transmission, mostly through the mucosa or contaminated needles. Uncontrolled viral replication is central to EBOV/MARV-induced disease, both because it is cytopathic and because it induces dysregulation of the host immune system (2, 7, 8). Therefore, antiviral therapies that reduce viral load are expected to increase patient survival, in part, by allowing time to mount an effective immune response. While many cell types can be infected with EBOV/MARV in vitro and in vivo, antigen-presenting cells (macrophages and dendritic cells) appear to be early and sustained targets of infection in vivo. Infected macrophages are unable to stimulate a robust immune response, and cause a “cytokine storm” that is proposed to be the primary cause of the bloodclotting abnormalities and vascular leakage characteristic of EBOV/MARV hemorrhagic fever (9). Damage to other tissues (e.g., liver, kidneys, vascular endothelia) is thought to contribute to the above and to late-stage multi-organ failure. Death typically occurs 8-15 days after infection (10). Because of their high mortality rate, rapid proliferation, and potential for aerosolization, EBOV and MARV are classified as Category A biodefense pathogens. There are currently no FDA-approved treatments for EBOV or MARV infection.

The EBOV/MARV genome is a ˜19 kb single-strand negative-sense RNA genome that encodes seven genes arranged in a linear fashion (1-4). In mature viral particles and infected cells, the genome is intimately associated with four viral proteins: the nucleocapsid protein NP, the polymerase L, the polymerase accessory protein VP35, and the transcriptional activator protein VP30. This nucleocapsid structure is in turn encapsidated in a viral matrix, comprising proteins VP40 and VP24. The host-derived viral membrane bilayer surrounds, and is peripherally associated with, the matrix. Embedded in the viral membrane are trimers of the viral glycoprotein, GP, which mediates the first step in infection: delivery of the viral nucleocapsid “payload” into the cytoplasm of the host cell. GP is the target of virus-directed antibodies that neutralize extracellular filovirus particles (4, 11-14).

The mature EBOV/MARV GP spike is a trimer of three disulfide-linked GP1-GP2 heterodimers, generated by endoproteolytic cleavage of the GP0 precursor polypeptide by furin during virus assembly (4, 13-15). GP1 mediates viral adhesion to host cells and regulates the activity of the transmembrane subunit GP2, which mediates fusion of viral and cellular membranes during cell entry. The prefusion GP1-GP2 spike has a “chalice-and-bowl” morphology—the three GP2 subunits form the chalice within which the bowl, comprised of the three GP1 subunits, rests (FIG. 1A) (13-15). This trimeric assembly is stabilized mainly by GP1-GP2 and GP2-GP2 contacts. The GP1 subunit is organized into three subdomains. The base (‘b’, light blue) interacts extensively with GP2 and clamps it in its prefusion conformation. The head (‘h’, green) contains a putative receptor-binding sequence. Together with GP2, the base and head subdomains of GP1 form the conserved structural core of the GP1-GP2 spike. In contrast to the GP1-GP2 core, the most external subdomains of GP1—the glycan cap (‘gc’, dark blue) and the mucin-like domain (not shown)—are extensively glycosylated and display a high degree of sequence variation among filovirus isolates. In response to a fusion trigger within host cell endosomes, GP2 disengages from GP1 and undergoes a series of large-scale conformational changes that drive coalescence of viral and cellular membrane bilayers (FIG. 1B) (4, 16-19). The result of viral membrane fusion is cytoplasmic release of the viral nucleocapsid. Neutralizing antibodies likely function by inhibiting these fusion-associated conformational changes (4, 13, 14).

The present invention addresses a need for improved treatments based on antibodies for filovirus infections.

SUMMARY OF THE INVENTION

The present invention addresses a need for improved treatments for filovirus infections.

This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region, and comprising

(a) (i) one or more of the following: a heavy chain CDR1 comprising GFAFNYYDM/I/LH (SEQ ID NO:1); a heavy chain CDR2 comprising YINPGGGNTYYADSV (SEQ ID NO:2); and a heavy chain CDR3 comprising QLYGNSFMDY (SEQ ID NO:3), or (ii) a heavy chain CDR3 comprising QLYGNSFFDY (SEQ ID NO:4), a heavy chain CDR1 comprising SEQ ID NO:1 or GFAFNYYDMF (SEQ ID NO:17), and a heavy chain CDR2 comprising SEQ ID NO:2, and (b) a light chain sequence, comprising a light chain CDR1, CDR2 and CDR3, wherein the light chain CDR3 comprises HYSTPLT (SEQ ID NO:5).

Also provided is an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region, and comprising (a) one or more of the following: a heavy chain CDR1 comprising GFAFNYYDMF (SEQ ID NO:17), a heavy chain CDR2 comprising YINPGGGNTYYPDSV (SEQ ID NO:18), a heavy chain CDR3 comprising QLYGNSFFDY (SEQ ID NO:19) and comprising (b) a light chain sequence, comprising at least (i) a light chain CDR3, which comprises HYSTPLT (SEQ ID NO:5) and (ii) comprising DIQMTQSPSSLSASVGDRVTITCKASQDVTTAVAWYQQKPGKAPKL (SEQ ID NO:20) and either (i) LIYAASGRYIGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ (SEQ ID NO:21) or (ii) LIYAASFLHRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ (SEQ ID NO:22).

Also provided is an antigen-binding fragment of any of the antibodies described herein.

Also provided is composition comprising any of the antibodies described herein or the antigen-binding fragments described herein. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.

Also provided is a method of treating a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of any of the antigen-binding fragments described herein or an amount of any of the compositions described herein effective to treat a filovirus infection in a subject.

Also provided is a method of inhibiting a filovirus infection of a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of any of the antigen-binding fragments described herein or an amount of any of the compositions described herein effective to inhibit a filovirus infection in a subject.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1B: Structure of the pre-fusion GP1-GP1 spike and GP conformational changes that lead to viral membrane fusion. FIG. 1A shows the structure of the GP1-GP2 spike ectodomain (PDB ID: 3CSY, ref. 13). The GP1 subunits are shown in surface-shaded view and GP2 as rods and loops. One GP1 subunit is colored to show the subdomains: b, base; h, head; gc, glycan cap. fp, fusion peptide. TM, transmembrane domain. C, GP C-terminus. FIG. 1B shows membrane fusion-associated conformational rearrangements in GP2 inferring from its pre-fusion and putative post-fusion structures (PDB ID: 1EBO, ref. 17).

FIG. 2: Survival of NHPs administered ZEBOV-specific serum IgGs upon viral challenge. Animals 7, 8, and 9 survived but the control animal (5) died 8-days post-exposure. These data are from ref 21 (Dye et al.).

FIG. 3: Head-to-head comparison of KZ52 IgG against VSV-GPZEBOV and 16F6 IgG against VSV-GPSUDV.

FIG. 4: Sequence alignment of YADS1 (an optimized Herceptin-based framework) and 16F6. The “chimera” represents the 16F6 CDR segments grafted on to the YADS1 scaffold. Residues identical to YADS1 shown in gray for 16F6 and the chimera. Sites of randomization in the humanization library indicated by ‘x’ on the chimera and highlighted. YADS1 Heavy Chain with CDR1 and CDR2 is SEQ ID NO:23; 16F6 Heavy Chain with CDR1 and CDR2 is SEQ ID NO:24; CHIMERA Heavy Chain with CDR1 and CDR2 is SEQ ID NO:25; YADS1 Heavy Chain with CDR3 is SEQ ID NO:26; 16F6 Heavy Chain with CDR3 is SEQ ID NO:27; CHIMERA Heavy Chain with CDR3 is SEQ ID NO:28; YADS1 Light Chain with CDR1 is SEQ ID NO:29; 16F6 Chain with CDR1 is SEQ ID NO:30; CHIMERA Light Chain with CDR1 is SEQ ID NO:31; YADS1 Light Chain with CDR2 and CDR3 is SEQ ID NO:32; 16F6 Light Chain with CDR2 and CDR3 is SEQ ID NO:33; CHIMERA Light Chain with CDR2 and CDR3 is SEQ ID NO:34.

FIG. 5: Structural alignment of YADS1 (cyan) and 16F6 (raspberry) variable domains.

FIGS. 6A-6B: Neutralization activity against VSV-GPSUDV. (A) Histogram plot of activity at 20 μM mAb concentration; (B) scatter plot at 5 μM or 20 μM mAb. Many of the humanized variants performed as well or better than 16F6. Twelve of the mAbs showed greater than 90% neutralization at 20 μM.

FIG. 7A-B: ELISA binding of E10 (FIG. 7A) and F4 (FIG. 7B) against GP from SUDV (Sudan) (filled circles), ZEBOV (Zaire), or 5% non-fat dry milk (NFDM) (triangles and squares).

FIG. 8: Sudan virus challenge dosing in mice: 500 ug of mAb/mouse at days (−1), (+1), and (+4)

FIG. 9: Re-challenge of surviving mice from FIG. 8.

FIG. 10: Challenge dosing: 500 ug of mAb/mouse at days (+1), and (+4). This experiment tests the “post-exposure” potential of the mAbs.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region, and comprising

(a) (i) one or more of the following: a heavy chain CDR1 comprising GFAFNYYDM/I/LH (SEQ ID NO:1); a heavy chain CDR2 comprising YINPGGGNTYYADSV (SEQ ID NO:2); and a heavy chain CDR3 comprising QLYGNSFMDY (SEQ ID NO:3), or (ii) a heavy chain CDR3 comprising QLYGNSFFDY (SEQ ID NO:4), a heavy chain CDR1 comprising SEQ ID NO:1 or GFAFNYYDMF (SEQ ID NO:17), and a heavy chain CDR2 comprising SEQ ID NO:2, and (b) a light chain sequence, comprising a light chain CDR1, CDR2 and CDR3, wherein the light chain CDR3 comprises HYSTPLT (SEQ ID NO:5).

In an embodiment, the heavy chain comprises the sequence EVQLVESGGGLVQPGGSLRLSCAASGFAFNYYDIHWVRQAPGKGLE (SEQ ID NO:6) or EVQLVESGGGLVQPGGSLRLSCAASGFAFNYYDLHWVRQAPGKGLE (SEQ ID NO:7) or EVQLVESGGGLVQPGGSLRLSCAASGFAFNYYDMHWVRQAPGKGLE (SEQ ID NO:8). In an embodiment, the heavy chain comprises the sequence WVAYINPGGGNTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA (SEQ ID NO:9). In an embodiment, the heavy chain comprises the sequence VYYCARQLYGNSFMDYWGQGTLVTV (SEQ ID NO:10) or VYYCARQLYGNSFFDYWGQGTLVTV (SEQ ID NO:11). In an embodiment, the light chain comprises the sequence DIQMTQSPSSLSASVGDRVTITCK/R/QASQDVTTAVAWYQQKPGKAPKL (SEQ ID NO:12).

In an embodiment, the light chain comprises the sequence LIYAASGRHKGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ (SEQ ID NO:13) or LIYAASRLHNGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ (SEQ ID NO:14) or LIYAASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ (SEQ ID NO:15). In an embodiment, the light chain comprises the sequence HYSTPLTFGQGTKVFI (SEQ ID NO:16).

Also provided is an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region, and comprising (a) one or more of the following: a heavy chain CDR1 comprising GFAFNYYDMF (SEQ ID NO:17), a heavy chain CDR2 comprising YINPGGGNTYYPDSV (SEQ ID NO:18), a heavy chain CDR3 comprising QLYGNSFFDY (SEQ ID NO:19) and comprising (b) a light chain sequence, comprising at least (i) a light chain CDR3, which comprises HYSTPLT (SEQ ID NO:5) and (ii) comprising DIQMTQSPSSLSASVGDRVTITCKASQDVTTAVAWYQQKPGKAPKL (SEQ ID NO:20) and either (i) LIYAASGRYIGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ (SEQ ID NO:21) or (ii) LIYAASFLHRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ (SEQ ID NO:22).

Also provided is an antigen-binding fragment of any of the antibodies described herein.

Also provided is composition comprising any of the antibodies described herein or the antigen-binding fragments described herein. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.

Also provided is a method of treating a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of any of the antigen-binding fragments described herein or an amount of any of the compositions described herein effective to treat a filovirus infection in a subject.

Also provided is a method of inhibiting a filovirus infection of a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of any of the antigen-binding fragments described herein or an amount of any of the compositions described herein effective to inhibit a filovirus infection in a subject.

In an embodiment of the methods, the antibody, antigen-binding fragment or composition are administered prior to the subject being exposed to the filovirus. In an embodiment of the methods, the antibody, antigen-binding fragment or composition are administered after the subject has been exposed to the filovirus. In an embodiment of the methods, the filovirus is an Ebola virus. In an embodiment of the methods, the Ebola virus is the Sudan strain. In an embodiment of the methods, the filovirus is a Marburg virus. In an embodiment of the methods, the filovirus is not a Marburg virus.

In an embodiment of any of the antibodies described herein, or any of the antigen-binding fragments described herein or any of the compositions described herein, or the methods described herein, the antibody is a neutralizing antibody. In an embodiment, the pre-fusion core is a heterohexamer of three copies of the GP1 and 3 copies of the GP2.

In an embodiment, the isolated antibody or antigen-binding antibody fragment comprises an Fc region having a sequence identical to a human Fc region.

In an embodiment, the Fc region of the antibody is glycosylated.

A “humanized” antibody as used herein, unless otherwise indicated, is a chimeric antibodies that contain minimal sequence (CDRs) derived from non-human immunoglobulin (e.g. such as a mouse immunoglobulin). In one embodiment, a humanized antibody is an antibody having a sequence of a human immunoglobulin (recipient antibody) in which CDR residues of a hypervariable region (HVR) of the recipient are replaced by CDR residues from a non-human species (donor antibody) such as a mouse having the desired specificity. In some instances, FR residues of the human immunoglobulin variable domain are replaced by corresponding non-human residues, for example by a back-mutation. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. See, e.g., Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); Presta, Curr. Op. Struct. Biol. 2:593-596 (1992); Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998); Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-433 (1994); and U.S. Pat. Nos. 6,982,321 and 7,087,409, the contents of each of which references and patents are hereby incorporated by reference in their entirety. Other techniques to humanize a monoclonal antibody are described in U.S. Pat. Nos. 4,816,567; 5,807,715; 5,866,692; 6,331,415; 5,530,101; 5,693,761; 5,693,762; 5,585,089; and 6,180,370, the content of each of which is hereby incorporated by reference in its entirety. The framework regions of the antibodies of the invention having a sequence identical to a human framework region may include amino acid residues not encoded by human germline sequences (e.g., mutations introduced by random or site-specific mutagenesis). In an embodiment, the isolated antibody or antigen-binding antibody fragment comprises a variable domain framework sequence having a sequence identical to a human variable domain framework sequence FR1, FR2, FR3 or FR4. In an embodiment, the isolated antibody or antigen-binding antibody fragment comprises a variable domain framework sequence having a sequence identical to at least two of human variable domain framework sequences FR1, FR2, FR3 or FR4. In an embodiment, the isolated antibody or antigen-binding antibody fragment comprises a variable domain framework sequence having a sequence identical to at least three of human variable domain framework sequences FR1, FR2, FR3 or FR4. In an embodiment, the isolated antibody or antigen-binding antibody fragment comprises a variable domain framework sequence having a sequence identical to all four of human variable domain framework sequences FR1, FR2, FR3 and FR4.

An isolated nucleic acid is provided encoding a VH or a VL of the antibodies, or fragments thereof, as described herein. In an embodiment, the isolated nucleic acid is a DNA. In an embodiment, the isolated nucleic acid is a cDNA. In an embodiment, the isolated nucleic acid is a RNA. A recombinant nucleic acid encoding an antibody as described herein is also provided. Also provided is a cell, wherein the cell is not in a human subject, transformed with the recombinant nucleic acid. In an embodiment, the cell is a mammalian cell. In an embodiment, the cell is derived from a human but is not in a human subject. In an embodiment, the cell is not a human cell.

As used herein, “at least 95% identical to” encompasses a sequence that has at least 95%, 96%, 97%, 98% or 99% identity with, or is 100% identical to, the referenced sequence. Accordingly, the individual embodiments of at least 95% identical to, at least 96% identical to, at least 97% identical to, at least 98% identical to, at least 99% identical to, and 100% identical to, are each all separately encompassed by the invention.

The antigen, in regard to the term “antigen-binding fragment” as used herein, is a filovirus glycoprotein pre-fusion core.

In an embodiment of the antibodies, fragments, methods and compositions described herein, the fragment of the antibody comprises an Fab, an Fab′, an F(ab′)2, an Fd, an Fv, or a complementarity determining region (CDR). In an embodiment, the fragment comprises a CDR3 of a VH chain. In an embodiment the fragment further comprises one of, more than one of, or all of CDR1, CDR2 of Vh and CDR1, CDR2 and CDR3 of a VL. As used herein, an Fd fragment means an antibody fragment that consists of the VH and CH1 domains; an Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment (Ward et al., Nature 341:544-546 (1989) hereby incorporated by reference in its entirety) consists of a VH domain. In some embodiments, fragments are at least 5, 6, 8 or 10 amino acids long. In other embodiments, the fragments are at least 14, at least 20, at least 50, or at least 70, 80, 90, 100, 150 or 200 amino acids long.

In an embodiment, the fragment of the antibody encompassed by the invention is a single-chain antibody (scFv) is a variable domain light chain (VL) and a variable domain heavy chain (VH) which are linked N—C or C—N, respectively, via a peptide linker. In an embodiment the linker of the scFv is 5-30 amino acids in length. In an embodiment the linker of the scFv is 10-25 amino acids in length. In an embodiment the peptide linker comprises glycine, serine and/or threonine residues. For example, see Bird et al., Science, 242: 423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA, 85:5879-5883 (1988), each of which are hereby incorporated by reference in their entirety. In an embodiment, the fragment of the antibody of the invention is not a single-chain antibody (scFv).

The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is often defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The C-terminal lysine of the Fc region may be removed, for example, during production or purification of the antibody, or by recombinantly engineering the nucleic acid encoding a heavy chain of the antibody. Accordingly, an intact antibody as used herein may be an antibody with or without the otherwise C-terminal cysteine.

In an embodiment, the antibodies of the invention described herein comprise a human Fc region or a variant human Fc region. A variant human Fc region comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one amino acid modification, yet retains at least one effector function of the native sequence human Fc region. Preferably, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g. from about one to about ten amino acid substitutions, and preferably, from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent polypeptide. The variant Fc region herein will preferably possess at least about 80% sequence identity with a native sequence Fc region and/or with an Fc region of a parent polypeptide, and most preferably, at least about 90% sequence identity therewith, more preferably, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity therewith.

Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is often defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The C-terminal lysine of the Fc region may be removed, for example, during production or purification of the antibody, or by recombinantly engineering the nucleic acid encoding a heavy chain of the antibody. Accordingly, an intact antibody as used herein may be an antibody with or without the otherwise C-terminal cysteine.

In an embodiment of the methods, the antibody, antibodies, antibody fragment or antibody fragments are administered as an adjuvant therapy to a primary therapy for the disease or condition.

The invention also provides diagnostic kits comprising any or all of the antibodies described herein. The diagnostic kits are useful for, for example, detecting the presence of a filovirus in a sample.

The humanized antibodies of the invention exclude any antibodies that naturally occur in a human.

As used herein, the term “isolated antibody” refers to an antibody that by virtue of its origin or source of derivation has one to four of the following characteristics: (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature.

The phrase “and/or” as used herein, with option A and/or option B for example, encompasses the embodiments of (i) option A, (ii) option B, and (iii) option A plus option B.

It is understood that wherever embodiments are described herein with the language “comprising,” otherwise analogous embodiments described in terms of “consisting of” and/or “consisting essentially of” are also provided.

Where aspects or embodiments of the invention are described in terms of a Markush group or other grouping of alternatives, the present invention encompasses not only the entire group listed as a whole, but each member of the group subjectly and all possible subgroups of the main group, but also the main group absent one or more of the group members. The present invention also envisages the explicit exclusion of one or more of any of the group members in the claimed invention.

All combinations of the various elements described herein are within the scope of the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

In the event that one or more of the literature and similar materials incorporated by reference herein differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.

This invention will be better understood from the Experimental Details, which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims that follow thereafter.

EXPERIMENTAL RESULTS Introduction

Immunotherapy is a tractable approach to filovirus treatment pre- and post-exposure: Until recently, it has been unclear if passive immunotherapy would be effective for treatment or prophylaxis of filovirus infection (20). However, two recent studies using non-human primate (NHP) models have provided convincing evidence that immunotherapy can and should be pursued (21, 22). Dr. Dye's laboratory reported that NHPs can be protected up to 48 hours post-exposure from MARV or ZEBOV infection by passive transfer of fractionated ZEBOV-specific IgG, or MARV-specific IgG, isolated from convalescent animals (same species) (21). In this study, two of the three NHPs that were challenged with ZEBOV, and then administered serum IgG, had no clinical signs of illness; the third developed mild, delayed signs of the disease but fully recovered (FIG. 2). The control animal died eight days post exposure. Similar results were obtained with MARV-challenged animals, suggesting that filovirus infection in general can be treated with antibodies. This protection required only three total administrations of the serum IgG (48 hours post exposure, then again at four and eight days). Therefore, antibody-based EBOV therapy is feasible, protective, and can be administered post-exposure. Earlier this year, Marzi et al. demonstrated that a combination therapy using two human-mouse chimeric monoclonal antibodies (mAbs) could partially protect NHPs against ZEBOV challenge (22). In this study, three NHPs were administered a cocktail of the two mAbs 24 hours preceding challenge with ZEBOV, then again 24- and 48-hours post-exposure. One of the three animals survived, one had delayed onset of hemorrhagic fever and was ultimately euthanized, and the other was similar to the control. From this work, it was concluded that the protection could be improved if serum half-life of the mAbs were optimized, or if the mAbs were used in combination with other mAbs or therapies. Enhanced neutralization potency would also likely improve protection, Given these recent findings, it appears that EBOV mAb therapy can be used prophylactically and acutely following exposure in humans.

Results Example 1

There is a gap in treatment of EBOV infection: Only a handful of animal challenge studies have been performed with mAb therapies, in part because few mAbs that target GP (the primary neutralization target) exist. Most antibodies elicited in natural infection react preferentially with a secreted, dimeric version of the glycoprotein known as sGP and do not neutralize the fusion-relevant GP spike (4, 23, 24). Wilson et al. first demonstrated that GP-specific neutralizing antibodies (nAbs) could protect mice from ZEBOV challenge (25). However, three of five protective antibodies recognize highly variable sequences within the GP1 mucin-like domain, rendering them unlikely candidates for development of cross-neutralizing mAbs. Antibodies KZ52 and 16F6 are among the few well-characterized nAbs and both bind to the GP prefusion core (elaborated further in Section 3b) (13, 14). KZ52 was identified by phage-based panning of a B-cell antibody library isolated from a human survivor of ZEBOV infection (26). Initial experiments in rodent protection studies were promising, but KZ52 failed to protect in macaques when administered on days −1 and +4 at 50 mg/kg (12, 20). However, it is possible that a more aggressive treatment regimen may provide protection. 16F6, a mouse mAb, was identified recently by Dr. Dye's group by vaccination with vector-based vaccine expressing SUDV GP (14). mAb 16F6 is much more potent than is KZ52 against the corresponding virus species, but its murine scaffold limits therapeutic utility at this point. Head-to-head comparison in neutralizations assays using a vesicular stomatitis virus pseudotype (VSV-GP) with KZ52 (against ZEBOV GP, GP_(ZEBOV)) and 16F6 (against SUDV GP, GP_(SUDV)) indicates that 16F6 can reduce infectivity by at least 10-fold more than KZ52 at high antibody concentrations (FIG. 3). The cause for this discrepancy is not clear, but these data nonetheless demonstrate that there is room for improvement in KZ52 activity. An immunocompetent mouse SUDV model is not available; however 16F6 treatment delays death of SCID mice challenged with SCID-adapted SUDV by 5-7 days (14). It is therefore likely that an optimized 16F6 variant will be protective.

Several candidate therapies and vaccines are under exploration for filovirus infection (27-33). Multiple promising vaccine candidates are able to protect NHPs from lethal challenge, including adenovirus-vectored, VSV-vectored, and virus-like particle-based vaccines (28-30). While any safe and effective EBOV vaccine will be useful for populations or workers that are at high risk for exposure, it is unlikely that vaccination against EBOV will be practical on a general population level. Therefore, there is still a need for an EBOV therapy that can be used to treat acute exposure or infection. Other biologics are under evaluation, including an antisense therapy undergoing clinical trials, and a promising RNAi therapy (31, 32). However, the use of nucleic acids as therapeutic agents in general is in its infancy and therefore there is a high barrier to FDA approval for such biologics. Furthermore, these therapeutic nucleic acids are strain-specific. Some small molecules against EBOV or host targets are also being explored, but studies are largely limited to early proof-of-concept stage (33-35). A mAb treatment has lower barriers to FDA approval than other therapeutic platforms given the broad use of mAbs in autoimmune diseases and cancer, as well as more recent use in prevention and treatment of infectious diseases (36).

Synthetic antibody engineering permits identification of antibodies with enhanced properties: Antibody phage display has emerged as a powerful alternative to hybridoma technology for the generation of mAbs (37-40). It is now possible to select high-affinity antibodies against virtually any antigen from phage libraries that bear tailored diversity elements encoded by synthetic DNA (“synthetic antibodies”) (41-45). This approach obviates the requirement for human or animal immunization, greatly reducing the labor and cost of antibody production. Selective enrichment of high-affinity binders from phage antibody libraries under controlled conditions enhances the reliability of output antibodies, and permits selection of binding with user-specified stringency (45). The expression of antibody domains on the surface of bacteriophage was first reported nearly two decades ago, but only recently have synthetic libraries (where diversity is not borne from natural source repertoires) become sophisticated enough for general use. Combined empirical and bioinformatic data guide predictions of locations in the antibody complementarity determining regions (CDRs) that favor antigen recognition (38, 41). The chemical (i.e., amino acid side chain) diversity encoded at these CDR positions can then be specified with designed codon sets that reduce sequence complexity but optimize combining site properties for molecular recognition (41, 42).

Humanizing SUDV-specific antibody 16F6 (“hu16F6”): 16F6 itself is of limited therapeutic utility because it is a murine antibody (14). (See also WO/2011/071574 for 16F6 antibodies. The contents of WO/2011/071574 are hereby incorporated by reference in their entirety). A sequence alignment of 16F6 in comparison to a synthetic antibody based on the optimized human framework of Herceptin (YADS1, ref. 48) is shown in FIG. 4, and a structural alignment of the variable domains shown in FIG. 5. Notably, 16F6 and YADS1 have high homology in the framework regions and the structural alignment shows that positioning of the CDR beginning and end points is similar among the two scaffolds. This analysis suggests that 16F6 can be humanized by grafting the 16F6 CDR segments onto the YADS1 framework to produce a 16F6-YADS1 chimera Fab. A summary of the steps is as follows:

Randomization is included at framework or structural (i.e., non-contact) CDR positions in a manner that permits the residue identity of 16F6, YADS1, or side chains with similar physicochemical attributes. Two positions on the YADS1 scaffold that correspond to contacting framework residues in 16F6 (T53 and T56) are diversified to allow for all 20 genetically-encoded amino acids. The ‘theoretical diversity’ of this library is 4×10⁷, which can be exhaustively sampled by phage display libraries that contain >10¹⁰ unique members. Neutralization of pseudotyped virus: The humanization library in FIG. 4 was constructed and screened against soluble GP from SUDV (GP_(SUDV)). Binding to the target was assessed at a preliminary level by phage ELISA. The most promising clones were produced as IgGs and screened for neutralization against vesicular stomatitis virus pseudotyped with GP_(SUDV) (VSV-GP_(SUDV)).

Neutralization of authentic SUDV: Clones E10 and F4 were tested for neutralization against authentic SUDV under BSL4 conditions at USAMRIID. E10 neutralized authentic SUDV by 80% or more at less than 0.625 μg/mL with and without complement. F4 neutralized authentic SUDV by 80% or more at less than 0.625 μg/mL with complement and 1.25 μg/mL without complement.

Additional Characterization of E10 and F4: Clones E10 and F4 were characterized for binding to GPSUDV by ELISA (FIG. 7). There was no cross-reactivity for GP from ZEBOV (GP Zaire) or 5% non-fat dry milk (NFDM). The half-maximal binding titers for GPSUDV were 17 nM for E10 and 5.1 nM for F4.

Sequences: The amino acid sequences of sixteen clones are shown below in alignment with 16F6 and YADS1 (only those amino acids that differ from 16F6 are shown). The CDRH1, CDRH2, CDRH3, and CDRL3 segments are underlined.

HEAVY CHAIN SEQUENCES: 16F6: EVQLVESGGGLVTPGGSLKLSCAASGFAFNYYDMFWVRQNTEKRLE YADS1:             Q     R        DIYDD IH    APG G E10:             Q     R              IH    APG G F4:             Q     R                    APG G 31C7:             Q     R                    APG G 31E3:             Q     R                    APG G 31F8:             Q     R                    APG G 31G11:             Q     R                    APG G 34F5:             Q     R                    APG G 35A1:             Q     R                    APG G 35B5:             Q     R                    APG G 41C6:             Q     R               H    APG G 41F10:             Q     R              LH    APG G 42F2:             Q     R                    APG G 51B6:             Q     R              LY    APG G 51F7:             Q     R                    APG G 52D11:             Q     R                    APG G 52F2:             Q     R               H    APG G 16F6: WVAYINSGGGNTYYPDTVKGRFTISRDNAKKTLFLQMSSLRSEDTA YADS1:      APSY Y D A S        A TS N AY   N   A E10:       P       A S        A TS N AY   N   A F4:       P       A S        A TS N AY   N   A 31C7:       P       A S        A TS N AY   N   A 31E3:       P         S        A TS N AY   N   A 31F8:               A S        A TS N AY   N   A 31G11:       P         S        A TS N AY   N   A 34F5:                 S        A TS N AY   N   A 35A1:       P         S        A TS N AY   N   A 35B5:                 S        A TS N AY   N   A 41C6:       P       A S        A TS N AY   N   A 41F10:            P       A S        A TS N AY   N   A 42F2:       P         S        A TS N AY   N   A 51B6:       P         S        A TS N AY   N   A 51F7:                 S        A TS N AY   N   A 52D11:       P         S        A TS N AY   N   A 52F2:       P       A S        A TS N AY   N   A 16F6: MYYCARQLYGNS---FFDYWGQGTSLTV YADS1: V   S SSDASYSYSAM       LV E10: V               M       LV F4: V                       LV 31C7: V               L       LV 31E3: V                       LV 31F8: V                       LV 31G11: V                       LV 34F5: V                       LV 35A1: V                       LV 35B5: V                       LV 41C6: V                       LV 41F10: V                       LV 42F2: V                       LV 51B6: V                       LV 51F7: V                       LV 52D11: V                       LV 52F2: V               M       LV LIGHT CHAIN SEQUENCES: 16F6: DIVMTQSHKFMSTSVGDRVTITCKASQDVTTAVAWYQQKPGHSPKL YADS1:     Q    PSSL A          R   ASYSS         KA E10:   Q    PSSL A          R                 KA F4:   Q    PSSL A                            KA 31C7:   Q    PSSL A                            KA 31E3:   Q    PSSL A                            KA 31F8:   Q    PSSL A                            KA 31G11:   Q    PSSL A                            KA 34F5:   Q    PSSL A                            KA 35A1:   Q    PSSL A          Q                 KA 35B5:   Q    PSSL A                            KA 41C6:   Q    PSSL A                            KA 41F10:   Q    PSSL A                            KA 42F2:   Q    PSSL A                            KA 51B6:   Q    PSSL A                            KA 51F7:   Q    PSSL A                            KA 52D11:   Q    PSSL A                            KA 52F2:   Q    PSSL A          Q                 KA 16F6: LIYWASTRHTGVPDRFTGSGSGTAFTLTLNSVQAEDLALYYCQQ YADS1:      A  YLYS   S  S      D    IS L P  F T    - E10:    A  RLHN   S  S      D    IS L P  F T F4:    A         S  S      D    IS L P  F T 31C7:    A  S YP   S  S      D    IS L P  F T 31E3:    A  G YI   S  S      D    IS L P  F T 31F8:    A         S  S      D    IS L P  F T 31G11:    A  S Y    S  S      D    IS L P  F T 34F5:    A  A  R   S  S      D    IS L P  F T 35A1:    A  SL F   S  S      D    IS L P  F T 35B5:    A         S  S      D    IS L P  F T 41C6:    A         S  S      D    IS L P  F T 41F10:    A         S  S      D    IS L P  F T 42F2:    A         S  S      D    IS L P  F T 51B6:    A         S  S      D    IS L P  F T 51F7:    A         S  S      D    IS L P  F T 52D11:    A  FL R   S  S      D    IS L P  F T 52F2:    A  G  K   S  S      D    IS L P  F T 16F6: HYSTPLTFGAGTKLFL YADS1: SSAS A   Q   V I E10:          Q   V I F4:          Q   V I 31C7:          Q   V I 31E3:          Q   V I 31F8:          Q   V I 31G11:          Q   V I 34F5:          Q   V I 35A1:          Q   V I 35B5:          Q   V I 41C6:          Q   V I 41F10:                Q   V I 42F2:          Q   V I 51B6:          Q   V I 51F7:          Q   V I 52D11:          Q   V I 52F2:          Q   V I

Example 2

Challenge: Interferon alpha/beta KO mice were challenged with 1000 pfu of Sudan Ebola virus (SUDV). mAb was administered as described in each panel (See FIG. 8). 16F6 (murine) and 6D8 were included as positive and negative controls respectively. Mortality and weight change were monitored. Re-challenge: Surviving mice from the challenge experiment were re-challenged at day 28 without antibody (except the negative control 6D8) (See FIG. 9). Mice that survive the re-challenge have long-lastinging immunity. (See FIGS. 8-10). (Antibodies E10 and F4 are encompassed by the invention. Antibodies 16F6 and 6D8 are positive and negative controls, respectively).

REFERENCES

-   1. Kuhn, J. H., Becker, S., Ebihara, H., Geisbert, T. W.,     Johnson, K. M., Kawaoka, Y., Lipkin, W. I., Negredo, A. I.,     Netesov, S. V., Nichol, S. T., Palacios, G., Peters, C. J., Tenorio,     A., Volchkov, V. E., and Jahrling, P. B. (2010) Proposal for a     revised taxonomy of the family Filoviridae: classification, names of     taxa and viruses, and virus abbreviations. Arch. Virol. 155,     2083-2103. -   2. Feldmann, H., and Gesibert, T. W. (2011) Ebola haemorrhagic     fever. Lancet 9768, 849-862. -   3. Miller, E. H., and Chandran, K. (2012) Filovirus entry into     cells—new insights. Curr. Opin. Virol. 2, 206-214. -   4. Lee, J. E., and Saphire, E. O. (2009) Neutralizing ebolavirus:     structural insights into the envelope glycoprotein and antibodies     targeted against it. Curr. Opin. Struct. Biol. 19, 408-417. -   5. Leroy, E. M., Kumulungui, B., Pourrut, X., Rouquet, P., Hassanin,     A., Yaba, P., Delicat, A., Paweska, J. T., Gonzalez, J. P., and     Swanepoel, R. (2005) Fruit bats as reservoirs of Ebola virus. Nature     438, 575-576. -   6. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/ebola.htm -   7. Bradfute, S. B., Warfield, K. L., and Bavari, S. (2008)     Functional CD8+ T cell responses in lethal Ebola virus infection. J.     Immunol. 180, 4058-4066. -   8. Zampieri, C. A., Sullivan, N. J., and Nabel, G. J. (2007)     Immunopathology of highly virulent pathogens: insights from Ebola     virus. Nat. Immunol. 8, 1159-1164. -   9. Geisbert, T. W., Hensley, L. E., Larsen, T., Young, H. A.,     Reed, D. S., Geisbert, J. B., Scott, D. P., Kagan, E., Jahrling, P.     B., and Davis, K. J. (2003) Pathogenesis of Ebola hemorrhagic fever     in cynomolgus macaques: evidence that dendritic cells are early and     sustained targets of infection. Am. J. Pathol. 163, 2347-2370. -   10. Hensley, L. E., Jones, S. M., Feldmann, H., Jahrling, P. B., and     Geisbert, T. W. (2005) Ebola and Marburg viruses: pathogenesis and     development of countermeasures. Curr. Mol. Med. 5, 761-772. -   11. Wilson, J. A., and Hart, M. K. (2001) Protection from Ebola     virus mediated by cytotoxic T lymphocytes specific for the viral     nucleoprotein. J. Virol. 75, 2660-2664. -   12. Parren, P. W., Geisbert, T. W., Maruyama, T., Jahrling, P. B.,     and Burton, D. R. (2002) Pre- and postexposure prophylaxis of Ebola     virus infection in an animal model by passive transfer of a     neutralizing human antibody. J. Virol. 76, 6408-6412. -   13. Lee, J. E., Fusco, M. L., Hessell, A. J., Oswald, W. B.,     Burton, D. R., and Saphire, E. O. (2008) Structure of the Ebola     virus glycoprotein bound to an antibody from a human survivor.     Nature 454, 177-182. -   14. Dias, J. M., Kuehne, A. I., Abelson, D. M., Bale, S., Wong, A.     C., Halfmann, P., Muhammad, M. A., Fusco, M. L., Zak, S. E., Kang,     E., Kawaoka, Y., Chandran, K., Dye, J. M., and Saphire, E. O. (2011)     A shared structural solution for neutralizing ebolaviruses. Nat.     Struct. Mol. Biol. 18, 1424-1427. -   15. Lee, J. E., and Saphire, E. O. (2009) Ebolavirus glycoprotein     structure and mechanism of entry. Future Virol. 4, 621-635. -   16. Weissenhorn, W., Carfi, A., Lee, K.-H., Skehel, J. J., and     Wiley, D. C. (1998) Crystal structure of the Ebola virus membrane     fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol.     Cell 2, 605-616. -   17. Malashkevich, V. N., Schneider, B. J., McNally, M. L.,     Milhollen, M. A., Pang, J. X., and Kim, P. S. (1999) Core structure     of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å     resolution. Proc. Natl. Acad. Sci. USA 96, 2662-2667. -   18. Harrison, J. S., Higgins, C. D., Chandran, K., and     Lai, J. R. (2011) Designed protein mimics of the Ebola virus     glycoprotein GP2 α-helical bundle: Stability and pH effects. Protein     Sci. 20, 1587-1596. -   19. Harrison, J. S., Koellhoffer, J. F., Chandran, K., and     Lai, J. R. (2012) Marburg virus glycoprotein GP2: pH-dependent     stability of the ectodomain α-helical bundle. Biochemistry 51,     2515-2525. -   20. Oswald, W. B., Geisbert, T. W., Davis, K. J., Geisbert, J. B.,     Sullivan, N. J., Jahrling, P. B., Parren, P. W., and     Burton, D. R. (2007) Neutralizing antibody fails to impact the     course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9. -   21. Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F.,     Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., and     Pratt, W. D. (2012) Postexposure antibody prophylaxis protects     nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. USA     109, 5034-5039. -   22. Marzi, A., Yoshida, R., Miyamoto, H., Ishijim, M., Suzuki, Y.,     Higuchi, M., Matsuyama, Y., Igarashi, M., Nakayama, E., Kuroda, M.,     Saijo, M., Feldmann, F., Brining, D., Feldmann, H., and     Takada A. (2012) Protective efficacy of neutralizing monoclonal     antibodies in a nonhuman primate model of Ebola hemorrhagic fever.     PLoS One 7, e36192. -   23. Wilson, J. A., Bosio, C. M., and Hart, M. K. (2001) Ebola virus:     the search for vaccines and treatments. Cell Mol. Life Sci. 58,     1826-1841. -   24. Sullivan, N. J., Martin, J. E., Graham, B. S., and     Nabel, G. J. (2009) Correlates of protective immunity for Ebola     vaccines: implications for regulatory approval by the animal rule.     Nat. Rev. Microbiol. 7, 393-400. -   25. Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M.,     Schmaljohn, A. L., and Hart, M. K. (2000) Epitopes involved in     antibody-mediated protection from Ebola virus. Science 287,     1664-1666. -   26. Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A.,     Khan, A. S., Nichol, S. T., Peters, C. J., Parren, P. W., and     Burton, D. R. (1999) Ebola virus can be effectively neutralized by     antibody produced in natural human infection. J. Virol. 73,     6024-6030. -   27. Shurtleff, A. C., Warren, T. K., and Bavari, S. (2011) Non-human     primates as models for the discovery and development of ebolavirus     therapeutics. Expert Opin. Drug Discov. 6, 233-250. -   28. Warfield, K. L., and Aman, M. J. (2011) Advances in virus-like     particle vaccines for filoviruses. J. Infect. Dis. 204 Suppl 3,     S1053-1059. -   29. Fausther-Bovendo, H., Mulangu, S., and Sullivan, N. J. (2012)     Ebolavirus vaccines for humans and apes. Curr. Opin. Virol. [Epub     ahead of print] (May 3, PMID: 22560007) -   30. Hoenen, T., Grosth, A., and Feldmann, H. (2012) Current ebola     vaccines. Expert Opin. Biol. Ther. [Epub ahead of print] (May 5,     PMID: 22559078) -   31. Warren, T. K., Warfield, K. L., Wells, J., Swenson, D. L.,     Donner, K. S., Van Tongeren, S. A., Garza, N. L., Dong, L.,     Mourich, D. V., Crumley, S., Nichols, D. K., Iversen, P. L., and     Bavari, S. (2010) Advanced antisense therapies for postexposure     protection against lethal filovirus infections. Nat. Med. 16,     991-994. -   32. Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B.,     Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I.,     Judge, A., Hensley, L. E., and Maclachlan, I. (2010) Postexposure     protection of non-human primates against a lethal Ebola virus     challenge with RNA interference: a proof-of-concept study. Lancet     375, 1896-1905. -   33. Panchal, R. G., Reid, S. P., Tran, J. P., Bergeron, A. A.,     Wells, J., Kota, K. P., Aman, J., and Bavari, S. (2012)     Identification of an antioxidant small-molecule with broad-spectrum     antiviral activity. Antiviral Res. 93, 23-29. -   34. Cote, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C.     M., Hensley, L., Li, Q., Ory, D., Chandran, K., and     Cunningham, J. (2011) Small molecule inhibitors reveal Niemann-Pick     C1 is essential for Ebola virus infection. Nature 477, 344-348. -   35. Basu, A., Li, B., Mills, D. M., Panchal, R. G., Cardinale, S.     C., Butler, M. M., Peet, N. P., Majgier-Baranowska, H., Williams, J.     D., Patel, I., Moir, D. T., Bavari, S., Ray, R., Farzan, M. R.,     Rong, L., and Bowlin, T. L. (2011) Identification of a     small-molecule entry inhibitor for filoviruses. J. Virol. 85,     3106-3119. -   36. Dimitrov, D. S., and Marks, J. D. (2009) Therapeutic antibodies:     current state and future trends—is a paradigm change coming soon?     Methods Mol. Biol. 525, 1-27. -   37. Lerner, R. A., Kang, A. S., Bain, J. D., Burton, D. R., and     Barbas, C. F. (1992) Antibodies without immunization. Science 258,     1313-1314. -   38. Sidhu, S. S., and Fellouse, F. A. Synthetic therapeutic     antibodies. (2006) Nat. Chem. Biol. 2, 682-688. -   39. Winter, G. (1998) Synthetic human antibodies and a strategy for     protein engineering. FEBS Lett. 430, 92-94. -   40. Lerner, R. A. (2006) Manufacturing immunity to disease in a test     tube: the magic bullet realized. Angew. Chem. Int. Ed. Engl. 48,     8106-8125. -   41. Fellouse, F. A., Esaki, K., Birtalan, S., Raptis, D.,     Cancasci, V. J., Koide, A., Jhurani, P., Vasser, M., Wiesmann, C.,     Kossiakoff, A. A., Koide, S., and Sidhu, S. S. (2007)     High-throughput generation of synthetic antibodies from highly     functional minimalist phage-displayed libraries. J. Mol. Biol. 373,     924-940. -   42. Fellouse, F. A., Li, B., Compaan, D. M., Peden, A. A.,     Hymowitz, S. G., and Sidhu, S. S. (2005) Molecular recognition by a     binary code. J. Mol. Biol. 348, 1153-1162. -   43. Liu, Y., Regula, L. K., Stewart, A., Lai, J. R. (2011) Synthetic     Fab fragments that bind the HIV-1 gp41 heptad repeat regions.     Biochem. Biophys. Res. Commun. 413, 611-615. -   44. Ye, J. D., Tereshko, V., Frederiksen, J. K., Koide, A.,     Fellouse, F. A., Sidhu, S. S., Kossiakoff, A. A., and     Piccirilli, J. A. (2008) Synthetic antibodies for specific     recognition and crystallization of structured RNA. Proc. Natl. Acad.     Sci. USA 105, 82-87. -   45. Gao, J., Sidhu, S. S., and Wells, J. A. (2009) Two-state     selection of conformation-specific antibodies. Proc. Natl. Acad.     Sci. USA 106, 3071-3076. -   46. Bostrom, J., Yu, S. F., Kan, D., Appleton, B. A., Lee, C. V.,     Billeci, K., Man, W., Peale, F., Ross, S., Weismann, C., and     Fuh, G. (2009) Variants of the antibody Herceptin that interact with     HER2 and VEGF at the antigen binding site. Science 323, 1610-1614. -   47. Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P., and     Cunningham, J. M. (2005) Endosomal proteolysis of the Ebola virus     glycoprotein is necessary for infection. Science 308, 1643-1645. -   48. Fellouse, F. A., Wiesmann, C., and Sidhu, S. S. (2004) Synthetic     antibodies from a four-amino-acid code: A dominant role for Tyrosine     in antigen recognition. Proc. Natl. Acad. Sci. USA 101, 12467-12472. -   49. Bostrom, J., Lee, C. V., Haber, L., and Fuh, G. Chapter 19:     Improving antibody binding affinity and specificity for therapeutic     development. In “Therapeutic Antibodies: Methods and Protocols”, vol     525, Dimitrov, A. S. (Ed). 2009. Humana Press: New York, N.Y. Pp     353-376. -   50. Pal, G., Kouadio, J. L., Ards, D. R., Kossiakoff, A. A., and     Sidhu, S. S. (2006) Comprehensive and quantitative mapping of energy     landscapes for protein-protein interactions by rapid combinatorial     scanning J. Biol. Chem. 281, 22378-22385. -   51. Pal, G., Fong, S. Y., Kossiakoff, A. A., and Sidhu, S. S. (2005)     Alternative views of functional protein binding epitopes obtained by     combinatorial shotgun scanning mutagenesis. Protein Sci. 14,     2405-2413. -   52. Weiss, G. A., Watanabe, C. K., Zhong, A., Goddard, A., and     Sidhu, S. S. (2000) Rapid mapping of protein functional epitopes by     combinatorial alanine scanning Proc. Natl. Acad. Sci. USA 97,     8950-8954. -   53. Vajdos, F. F., Adams, C. W., Breece, T. N., Presta, L. G., de     Vos, A. M., and Sidhu, S. S. (2002) Comprehensive functional maps of     the antigen-binding site of an anti-ErbB2 antibody obtained with     shotgun scanning mutagenesis. J. Mol. Biol. 320, 415-428. -   54. Da Silva, G. F., Harrison, J. S., and Lai, J. R. (2010)     Contribution of light chain residues to high affinity binding in an     HIV-1 antibody explored by combinatorial scanning mutagenesis.     Biochemistry 49, 5464-5472. -   55. Clackson, T., and Wells, J. A. (1995) A hot spot of binding     energy in a hormone-receptor interface. Science 267, 383-386. -   56. Kouadio, J. L., Horn, J. R., Pal, G., and     Kossiakoff, A. A. (2005) Shotgun alanine scanning shows that growth     hormone can bind productively to its receptor through a drastically     minimized interface. J. Biol. Chem. 280, 25524-25532. -   57. Mazor, Y., Barnea, I., Keydar, I., and Benhar, I. (2007)     Antibody internalization studied using a novel IgG binding toxin     fusion. J. Immunol. Methods 321, 41-59. -   58. Phoolcharoen, W., Dye, J. M., Kilbourne, J., Piensook, K.,     Pratt, W. D., Arntzen, C. J., Chen, Q., Mason, H. S.,     Herbst-Kralovetz, M. M. (2011) A nonreplicating subunit vaccine     protects mice against lethal Ebola virus challenge. Proc. Natl.     Acad. Sci. USA 108, 20695-20700. 

What is claimed:
 1. An isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region, and comprising (a) a heavy chain CDR1 comprising GFAFNYYDM/I/LH (SEQ ID NO:1); a heavy chain CDR2 comprising YINPGGGNTYYADSV (SEQ ID NO:2); and a heavy chain CDR3 comprising QLYGNSFMDY (SEQ ID NO:3), and (b) a light chain sequence, comprising a light chain CDR1, CDR2 and CDR3, wherein the light chain comprises DIQMTQSPSSLSASVGDRVTITCK/R/QASQDVTTAVAWYQQKPGKAPKL (SEQ ID NO:12) and LIYAASRLHNGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ (SEQ ID NO:14) and wherein the CDR3 comprises HYSTPLT (SEQ ID NO:5).
 2. The humanized antibody of claim 1, wherein the heavy chain comprises the sequence EVQLVESGGGLVQPGGSLRLSCAASGFAFNYYDIHWVRQAPGKGLE (SEQ ID NO:6).
 3. The humanized antibody of claim 1, wherein the heavy chain comprises the sequence WVAYINPGGGNTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA (SEQ ID NO:9).
 4. The humanized antibody of claim 1, wherein the heavy chain comprises the sequence VYYCARQLYGNSFMDYWGQGTLVTV (SEQ ID NO:10).
 5. The humanized antibody of claim 1, wherein the light chain comprises the sequence HYSTPLTFGQGTKVFI (SEQ ID NO:16).
 6. A composition comprising the antibody of claim 1 or an antigen-binding fragment thereof.
 7. The composition of claim 6, comprising a pharmaceutically acceptably carrier.
 8. A method of inhibiting an Ebola virus infection of a subject comprising administering to the subject an amount of the antibody of claim 1 or an antigen-binding fragment thereof effective to inhibit an Ebola virus infection in a subject, wherein administration is prior to the subject being exposed to the Ebola virus, further wherein the Ebola virus is the Sudan strain, and further wherein heavy chain CDR1 comprises GFAFNYYDIH (SEQ ID NO: 1) and the light chain comprises DIQMTQSPSSLSASVGDRVTITCRASQDVTTAVAWYQQKPGKAPKL (SEQ ID NO: 12). 